Arbutus Biopharma Corp
NASDAQ:ABUS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Arbutus Biopharma Corp
Net Change in Cash
Arbutus Biopharma Corp
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arbutus Biopharma Corp
NASDAQ:ABUS
|
Net Change in Cash
-$18.3m
|
CAGR 3-Years
38%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Change in Cash
-$295m
|
CAGR 3-Years
19%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Change in Cash
-$2.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Change in Cash
-$2.8B
|
CAGR 3-Years
-99%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Change in Cash
$515.6m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
19%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Change in Cash
$634.7m
|
CAGR 3-Years
42%
|
CAGR 5-Years
2%
|
CAGR 10-Years
15%
|
|
Arbutus Biopharma Corp
Glance View
Arbutus Biopharma Corp. is a biopharmaceutical company. The company is headquartered in Warminster, Pennsylvania and currently employs 85 full-time employees. The company went IPO on 2010-11-13. The firm is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, oral capsid inhibitor, an oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The firm is having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses (including SARS-CoV-2).
See Also
What is Arbutus Biopharma Corp's Net Change in Cash?
Net Change in Cash
-18.3m
USD
Based on the financial report for Dec 31, 2025, Arbutus Biopharma Corp's Net Change in Cash amounts to -18.3m USD.
What is Arbutus Biopharma Corp's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
38%
The average annual Net Change in Cash growth rates for Arbutus Biopharma Corp have been 38% over the past three years .
